Insulin Resistance presentations about Insulin Resistance EB with interest for Insulin Resistance Validating Insulin Resistance content Free registration form / enregistrement gratuit
1
2
  Franšais - August 16, 2011
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.

CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
 Presentation

"Managing Type 2 Diabetes: More than Sugar"

Dr. Lawrence A. Leiter (biography)
English - 2002-11-16 - 33 minutes
(48 slides)

Summary :
Cardiovascular disease accounts for about 80% of deaths in individuals with diabetes. There is no doubt that this increased atherosclerosis is a result of multiple factors. Studies such as the DCCT in individuals with TYPE 1 diabetes and the UKPDS in persons with Type 2 Diabetes have shown that improved glycemic control clearly reduces the risk for microvascular complications. In neither study, however, were macrovascular complications decreased significantly. This may be a result of the treatments that were employed, as it has been suggested that treatments that directly reduce insulin resistance may result in additional vascular benefit. There is, in fact, increasing evidence that the insulin sensitizers may improve not only traditional risk factors, but also a number of inflammatory factors that are also intimately involved in the pathogenesis of atherosclerosis. The relative lack of benefit seen in the clinical trials may also reflect the fact that improved glycemic control, without simultaneous aggressive management of the other cardiovascular risk factors, is insufficient to reduce the risk for vascular disease.
Until recently, data on the benefits of cholesterol reduction with stains in individuals with diabetes were limited to relatively small subset analyses from the major statin trials. The Heart Protection Study, however, included about 6000 persons with diabetes (10% Type 1 and 90% Type 2), both primary and secondary prevention, and demonstrated that treatment with 40 mg simvastatin daily reduced the risk for not only coronary artery disease but also for stroke by about 25%. The observed effect was independent of baseline cholesterol levels, i.e., even those subjects with realtively low LDL levels at baseline showed benefit. Trials using fibrates including the VA-HIT and DAIS have also shown benefit in persons with diabetes.
There is also increasing evidence on the value of aggressive management of blood pressure in diabetes. Studies including the UKPDS and HOT trials have clearly shown that intensive blood pressure management results in a greater reduction in both microvascular and macrovascular complications than more moderate blood pressure control. At the same time, there is also evidence that the antihypertensive agent chosen may also determine the event reduction. Studies utilizing both ACE inhibitors and ARBs have demonstrated additional benefit. At the same time it should be noted that most diabetic patients will require 3-4 antihypertensive drugs to reach the current aggressive targets.

   


  Login
  Username :
  Password :
   
  Lost your password?


  Search our website
  Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes.
 

  Social
  Let others know about this presentation.

 Del.icio.us
 Digg!



MULTILEARNING - MULTIWEBCAST - MULTIEPOSTER - MULTIEPORTAL

Copyright © 2002-2015 MULTILEARNING Group INC.. All rights reserved.  Disclaimer
Powered by Multiwebcast - webcast services


USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
insulin resistanceC-Reactive Protein (CRP)CRP, C-Reactive ProteinADHD ADDdiabetes insulin